


Curriculum Vitae

Name	Jeffrey S Weber MD PhD	
Current Position & Affiliation	Deputy Director, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health	
Country	USA	

Educational Background

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	Completion Date MM/YYYY	FIELD OF STUDY
Columbia University, New York, NY	BA	06/1972	Biology
Rockefeller University, New York, NY	PhD	06/1979	Molecular Cell Biology
New York University School of Medicine	MD	06/1980	Medicine

Professional Experience

1980-1983	Intern and Resident in Medicine, UCSD Medical Center, San Diego, CA
1985-1986	Clinical Associate, Medicine Branch, NCI/NIH, Bethesda, MD
1986-1990	Medical Staff and Senior Staff Fellow, Surgery Branch, NCLINIH, Bethesda, MD
1990-1994	Senior Investigator, Surgery Branch, NCI/NIH, Bethesda, MD
1994-1995	Assistant Professor of Medicine, University of California, Irvine, CA
1995-2005	Associate Professor of Medicine and Molecular Microbiology & Immunology, Division of Medical Oncology, University of Southern California, Los Angeles, CA
1998-2007	Head, Developmental Therapeutics Program, USC/Norris Comprehensive Cancer Center
2001-2007	Lucille and Berle Adams Chair in Cancer Research
2003-2007	Chief of Medical Oncology, Department of Medicine, Keck USC School of Medicine, Los Angeles, CA

2003-2007	Associate Director for Clinical Research, USC/Norris Comprehensive Cancer Center, Los Angeles, CA
2005-2007	Adams Professor of Medicine, Molecular Microbiology and Immunology, Division of Medical Oncology, University of Southern California, Los Angeles, CA
2007-2015	Director, Donald A. Adam Comprehensive Melanoma Research Center, H. Lee Moffitt Comprehensive Cancer Center, Tampa, FL
2007-2015	Senior Member and Donald A Adam Professor, H. Lee Moffitt Comprehensive Cancer Center, Tampa, FL
2015-present	Deputy Director, and Head, Experimental Therapeutics, Laura and Isaac Perlmutter Comprehensive Cancer Center
2015-present	Professor of Medicine and Laura and Isaac Perlmutter Professor of Oncology, NYU Grossman School of Medicine

Professional Organizations

ASCO
AACR
SITC

Main Scientific Publications

1. Yusko E, Vignali M, Wilson RK*, Mardis ER, Stephen Hodi FS, Horak C, Chang H, Woods DM, Robins H and **Weber J.** Association of Tumor Microenvironment T-Cell Repertoire and Mutational Load With Clinical Outcome After Sequential Checkpoint Blockade in Melanoma. *Cancer Immunol Res* 2019 7(3):458-465. PMID: PMC6397694
2. **Weber JS**, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA, Capone M, Oliveira C, Meyer K, Grigorieva J, Asmellash SG, Roder J, Roder H. A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. *Cancer Immunol Res.* 2018 Jan;6(1):79-86.
3. Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, **Weber J** Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. *J Immunother Cancer.* 2020 Jun;8(1):e000842.
4. **Weber J**, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler

MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater

J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *N Engl J Med*. 2017 Nov 9;377(19):1824-1835.

5. Yoshida T, Ichikawa J, Giuroiu I, Laino AS, Hao Y, Krosggaard M, Vassallo M, Woods DM, Hodi FS and **Weber J**. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
J Immunother of Cancer 2020 Apr;8(1):e000234
6. Ichikawa J, Yoshida T, Isser AY, Laino AS, Vassallo M, Woods DM, Kim S, Oelke M, Jones K, Schneck JP and **Weber JS** Rapid Expansion of Highly Functional Antigen-Specific T cells from Melanoma Patients by Nanoscale Artificial Antigen Presenting Cells 2020 *Clin Can Res* Jul 1;26(13):3384-3396
7. Ascierto PA, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Maio M, Middleton MR, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Lobo M, de Pril V, Loffredo J, Larkin J, **Weber J**. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol. 2020
8. **Weber JS**, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, Jiang J, Robert C. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. *J Clin Oncol*. 2017 Mar;35(7):785-792.